Frontlight ResearchEarly access
CompletedPhase 2
Efficacy and Safety of Liuwei Dihuang Pill Versus Placebo in Presbycusis With Shen (Kidney)-Yin Deficiency
Key facts
- Who runs it
- Shanghai Jiao Tong University School of Medicine
- Where
- China6 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 120 people enrolled
- Started
- 25 Jan 2022
- Ended
- 25 Dec 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Liuwei Dihuang Pill (marketed product in China)
- Liuwei Dihuang Pill(placebo )
- Record updated
- 7 January 2026
Who can take part
- Age
- 65 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (15)Hide the full registry criteria
Who can take part
- Subjects must have a current diagnosis of presbyacusis with symmetrical hearing loss, defined as 15-dB or less difference in pure tone average between ears at 0.5, 1, 2 and 4kHz. The average hearing threshold loss level is mild or moderate (20 ≤ average hearing threshold < 50 dBHL)
- Adult aged 65-75 years inclusive
- Maximum speech recognition rate in quiet environment is equal to or over 60% with ability to communicate well
- Subjects have no cognitive impairment with CDR score =0
- Subjects must have a current diagnosis of Shen (Kidney)-Yin Deficiency
- Subjects have read and voluntarily signed the Informed Consent Form (ICF) after all questions have been answered and prior to any study-mandated procedure
Who cannot take part
- Subjects has previously participated in other clinical trial within the three months
- Subjects with a history of serious mental illness
- Subjects with severe cardiac insufficiency, malignant tumor or other serious systemic diseases
- Subjects with conductive deafness, congenital deafness, hereditary deafness, inner ear immune and autoimmune inner ear diseases, auditory neuropathy, toxic deafness and noise deafness
- Subjects with organic ear diseases, abnormal ear structure and symptomatic cerebral infarction
- Subjects with dementia, neurosyphilis, hypothyroidism and depression
- Subjects with sudden hearing loss or pure tone hearing fluctuation within the three months
- Subjects with using hearing aids or devices
- Other situations where the researcher thinks it is inappropriate to participate in this research
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The objective of this study is to examine the effects and safety of Liuwei Dihuang pill and placebo in presbycusis with Shen (kidney)-yin deficiency.
The 2 groups in the trial
- LDP groupTreatment being tested
Liuwei Dihuang Pill (LDP)marketed product in China donated by pharmaceutical company.
Treatment: Liuwei Dihuang Pill (marketed product in China)
- placebo groupPlacebo, for comparison
Same smell, color and shape as Liuwei Dihuang Pill (LDP)without herbs in capsules.
Treatment: Liuwei Dihuang Pill(placebo )
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- RCT Study of Liuwei Dihuang Pill Preventing and Treating Presbycusis With Shen (Kidney)-Yin Deficiency
- Record updated
- 7 January 2026